

Amendments to the Claims:**Claims 1-46 (canceled).**

47. (Amended) A nucleic acid comprising a nucleic acid sequence encoding a ~~polypeptide comprising~~ an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5.
48. (Previously presented) A vector comprising the nucleic acid of claim 47.
49. (Previously presented) The vector of claim 48, wherein the vector is selected from the group consisting of *E. coli* plasmid, *Listeria* vector, orthopox virus, avipox virus, capripox virus, suipox virus, vaccinia virus, baculovirus, human adenovirus, SV40 virus and bovine papilloma virus.
50. (Previously presented) The vector of claim 49 further comprising a nucleotide sequence encoding at least one HLA class I molecule.
51. (Previously presented) A host cell comprising the vector of claim 50.
52. (Previously presented) A kit comprising the vector of claim 48.
53. (Previously presented) The kit according to claim 52 further comprising an immunostimulatory molecule.
54. (Previously presented) The kit according to claim 52, wherein said vector comprises a nucleic acid comprising the nucleic acid sequence encoding SEQ ID NO:2.
55. (Previously presented) The kit according to claim 53, wherein the immunostimulatory molecule is GM-CSF.
56. (Previously presented) The vector of claim 50, wherein the HLA Class I molecule is HLA-A2.
57. (New) The nucleic acid of claim 47, wherein said nucleic acid encodes an amino acid sequence which is capable of stimulating a CEA specific cytolytic cytotoxic T lymphocyte (CTL) response in a subject.